Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma

Japanese Journal of Clinical Oncology

Volumn 46, Issue 1, 2016, Pages 86-88

  Shirai, Takushi ^a   Sano, Tasuku ^a   Kamijo, Fuminao ^a   Saito, Nana ^a   Miyake, Tomomi ^a   Kodaira, Minori ^a   Katoh, Nagaaki ^a   Nishie, Kenichi ^a   Okuyama, Ryuhei ^a   Uhara, Hisashi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Melanoma; Myasthenia gravis; Nivolumab; PD 1; Rhabdomyolysis

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; EDROPHONIUM; METHYLPREDNISOLONE; NIVOLUMAB; ANTINEOPLASTIC AGENT; AUTOANTIBODY; CHOLINERGIC RECEPTOR; MONOCLONAL ANTIBODY;

AGED; ANTIBODY TITER; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DIAPHRAGM DISEASE; DIPLOPIA; DISEASE COURSE; DISEASE EXACERBATION; DYSPNEA; ECHOGRAPHY; FATIGUE; FEMALE; HEPATITIS; HUMAN; METASTATIC MELANOMA; MONOTHERAPY; MUSCLE WEAKNESS; MYALGIA; MYASTHENIA GRAVIS; PHYSICAL EXAMINATION; PTOSIS; RHABDOMYOLYSIS; SYMPTOM; VERY ELDERLY; BLOOD; CHEMICALLY INDUCED; IMMUNOLOGY; MELANOMA; SKIN NEOPLASMS;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; FEMALE; HUMANS; MELANOMA; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; RHABDOMYOLYSIS; SKIN NEOPLASMS;

EID: 84954530274     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyv158     Document Type: Article

References (15)

1. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med 2015;372:320-30.
2. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521-32.
3. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-24.
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
5. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of responsewith ipilimumab. J Clin Oncol 2012;30:2691-7.
6. Johnson DB, Saranga-Perry V, Lavin PJ, Brunette B, Clark SW, Uskavitch DR, et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol 2014;94:462-9.
7. Loochtan AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 2015;52:307-8.
8. Wang HB, Shi FD, Li H, Chambers BJ, Link H, Ljunggren HG. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol 2001;166:6430-6.
9. Sakthivel P, Ramanujam R, Wang XB, Pirskanen R, Lefvert AK. Programmed death-1: from gene to protein in autoimmune human myasthenia gravis. J Neuroimmunol 2008;193:149-55.
10. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054-9.
11. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-8.
12. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330:1797-810.
13. Boelaert K, Newby PR, Simmonds MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med 2010;123:183 e181-189.
14. Tanaka M, Miyatake T. Anti-acetylcholine receptor antibody in aged individuals and in patients with Down's syndrome. J Neuroimmunol 1983; 4:17-24.
15. Min L, Hodi FS. Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res 2014;2:15-8.